secwatch.observer — SEC 8-K summary
======================================

Issuer:     Moleculin Biotech, Inc. (MBRX)
CIK:        0001659617
Form:       8-K
Filed at:   2025-08-13T23:59:59+00:00
Accession:  0001437749-25-026357
Event type: earnings
Sentiment:  negative
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Moleculin Q2 2025 cash $7.6M; R&D expense down to $3.6M; MIRACLE trial data readout expected by year-end
--------------------------------------------------------------------------------

- Cash and equivalents $7.6M at June 30, 2025, expected to fund operations only into Q4 2025.
- R&D expense $3.6M for Q2 2025, down $0.5M from $4.1M in Q2 2024 due to reduced clinical trial activity.
- G&A expense flat at $2.1M; no revenue reported for the quarter.
- MIRACLE Phase 2B/3 trial expanded to 4 active sites in US, EU, and Georgia; 20+ additional sites expected by end of Q3 2025.
- Anticipated unblinded data readout from first 45 subjects in MIRACLE Part A before end of 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1659617/000143774925026357/0001437749-25-026357-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1659617/000143774925026357/mbrx20250811_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-25-026357

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer